AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19190453 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic cortical venous drainage (sCVD)
Number of subjects: 28
Study 19190453 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of aCVD vs sCVD
Number of subjects: 28
Study 17126653 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus team case management
Number of subjects: 148
Study 17126653 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study 15501836 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (600,000 i.u. ergocalciferol)
Number of subjects: 139
Study 15501836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 11171729 — intervention group
Group type: EXPERIMENTAL
Intervention: IV combination of diltiazem and digoxin
Number of subjects: 52
Study 11171729 — intervention group
Group type: COMPARATOR
Intervention: IV diltiazem alone
Number of subjects: 52
Study 9603556 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical orthopedic treatment (PSOT)
Number of subjects: 52
Study 9603556 — intervention group
Group type: COMPARATOR
Intervention: Non-presurgical orthopedic treatment (non-PSOT)
Number of subjects: 52
Study 9603556 — intervention group
Group type: EXPERIMENTAL
Intervention: PSOT
Number of subjects: 52
Study 9603556 — intervention group
Group type: COMPARATOR
Intervention: non-PSOT
Number of subjects: 52
Study 7997340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Guidance Orthosis (HGO)
Number of subjects: 28
Study 7997340 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating Gait Orthosis (RGO)
Number of subjects: 28
Study 7997340 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Reciprocating Gait Orthosis (ARGO)
Number of subjects: 28
Study 7997340 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall use of orthoses
Number of subjects: 28
Study 3276384 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional hyperthermic cytostatic perfusion with melphalan (42 degrees C)
Number of subjects: 107
Study 3276384 — intervention group
Group type: COMPARATOR
Intervention: Control group (wide excision and lymph node dissection)
Number of subjects: 107
Study 30348455 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping with tension (KTT)
Number of subjects: 108
Study 30348455 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping no tension (KTNT)
Number of subjects: 108
Study 30348455 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 108
Study 28492456 — intervention group
Group type: EXPERIMENTAL
Intervention: Calmer Life (CL) intervention, a community-based, person-centered, flexible and culturally tailored intervention for late-life anxiety and worry.
Number of subjects: 0
Study 26478577 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (performed more than two times every week for 50-60 minutes each time after work hours)
Number of subjects: 120
Study 26478577 — intervention group
Group type: COMPARATOR
Intervention: Non-yoga group (did not participate in yoga)
Number of subjects: 120
Study 23428009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 76
Study 20854308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis with a duty cycle of 80%
Number of subjects: 0
Study 20854308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis with a duty cycle of 70%
Number of subjects: 0
Study 20854308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis with a duty cycle of 60%
Number of subjects: 0
Study 19242403 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone + clarithromycin
Number of subjects: 10
Study 19242403 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem + clarithromycin
Number of subjects: 10
Study 19242403 — intervention group
Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 10
Study 19242403 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem + placebo
Number of subjects: 10
Study 19242403 — intervention group
Group type: COMPARATOR
Intervention: Trazodone + placebo
Number of subjects: 10
Study 16757723 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization
Number of subjects: 302
Study 16757723 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization
Number of subjects: 302
Study 16757723 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization (hospital survivors)
Number of subjects: 302
Study 16757723 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization (hospital survivors)
Number of subjects: 302
Study 16757723 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization (1-year survivors)
Number of subjects: 302
Study 16757723 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization (1-year survivors)
Number of subjects: 302
Study 15121648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 288
Study 15121648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 288
Study 15121648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 15121648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (both doses)
Number of subjects: 288
Study 11698228 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC group)
Number of subjects: 31
Study 11698228 — intervention group
Group type: COMPARATOR
Intervention: Protease Inhibitors (PI group)
Number of subjects: 31
Study 9480226 — intervention group
Group type: EXPERIMENTAL
Intervention: Placentas from women in the phenol polluted area (Płock)
Number of subjects: 226
Study 9480226 — intervention group
Group type: COMPARATOR
Intervention: Control group (Kutno) placentas
Number of subjects: 226
Study 7879746 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented condition (Education and Peer Support Components)
Number of subjects: 145
Study 7879746 — intervention group
Group type: COMPARATOR
Intervention: Minimal condition (Education Component)
Number of subjects: 145
Study 3041555 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injections of OK-432 plus systemic treatment (5-fluorouracil)
Number of subjects: 48
Study 3041555 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 48
Study 30782687 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C reduction to <120-160 mg/dL (group A)
Number of subjects: 0
Study 30782687 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C reduction to <70 mg/dL (group B)
Number of subjects: 0
Study 28087548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens extraction
Number of subjects: 0
Study 28087548 — intervention group
Group type: COMPARATOR
Intervention: Standard care (laser iridotomy followed by medical therapy and glaucoma surgery)
Number of subjects: 0
Study 26269241 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-based breakfast (PRO)
Number of subjects: 29
Study 26269241 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-based breakfast (CHO)
Number of subjects: 29
Study 23142493 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylphenidate (MPH) 35 mg (approximately 0.5 mg/kg)
Number of subjects: 16
Study 23142493 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 16
Study 23142493 — intervention group
Group type: EXPERIMENTAL
Intervention: dAMPH users
Number of subjects: 16
Study 21238643 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm pacing (DP)
Number of subjects: 6
Study 18481293 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids administered before biopsy
Number of subjects: 109
Study 18481293 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroids administered before biopsy
Number of subjects: 109
Study 22545653 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of familism
Number of subjects: 5646
Study 22545653 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of parental respect
Number of subjects: 5646
Study 22545653 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement properties of familism and parental respect
Number of subjects: 5646
Study 15946237 — intervention group
Group type: COMPARATOR
Intervention: Topical application of niacinamide
Number of subjects: 0
Study 15946237 — intervention group
Group type: EXPERIMENTAL
Intervention: Lectins and niacinamide
Number of subjects: 0
Study 15946237 — intervention group
Group type: EXPERIMENTAL
Intervention: Lectins
Number of subjects: 0
Study 15946237 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoglycoproteins
Number of subjects: 0
Study 12894014 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 100
Study 12894014 — intervention group
Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 100
Study 10480514 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 1245
Study 10480514 — intervention group
Group type: COMPARATOR
Intervention: Fasting glucose alone
Number of subjects: 1245
Study 10480514 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal fasting glucose and postload hyperglycemia
Number of subjects: 1245
Study 10480514 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia
Number of subjects: 1245
Study 7766741 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg b.d. for 7 days every month plus glucomannan 2 g/day
Number of subjects: 168
Study 7766741 — intervention group
Group type: COMPARATOR
Intervention: Placebo two tablets b.d. for 7 days every month plus glucomannan 2 g/day
Number of subjects: 168
Study 7766741 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 168
Study 2187384 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 40
Study 2187384 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 399319 — intervention group
Group type: EXPERIMENTAL
Intervention: Midecacin (CM 9164)
Number of subjects: 2
Study 399319 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 2
Study 12970233 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (intravenous infusion for the first 24 hours at 1050 mg total, followed by oral therapy for 4 postoperative days at 4800 mg total)
Number of subjects: 160
Study 12970233 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone + Atrial Septal Pacing (96 hours)
Number of subjects: 160
Study 12970233 — intervention group
Group type: COMPARATOR
Intervention: Atrial Septal Pacing (96 hours)
Number of subjects: 160
Study 12970233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 29882203 — intervention group
Group type: EXPERIMENTAL
Intervention: Niclosamide (NCL) 1000 mg/day
Number of subjects: 110
Study 29882203 — intervention group
Group type: COMPARATOR
Intervention: Lactose (placebo) 1000 mg/day
Number of subjects: 110
Study 27687464 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group (listened to Vivaldi's The Four Seasons by sound-isolating headphones)
Number of subjects: 180
Study 27687464 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation group (wore headphones but did not listen to music)
Number of subjects: 180
Study 27687464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music or sound isolation)
Number of subjects: 180
Study 24887107 — intervention group
Group type: EXPERIMENTAL
Intervention: Social involvement with a wider variety of people and groups
Number of subjects: 300
Study 24887107 — intervention group
Group type: EXPERIMENTAL
Intervention: Support work undertaken by personal networks
Number of subjects: 300
Study 24887107 — intervention group
Group type: EXPERIMENTAL
Intervention: Network support
Number of subjects: 300
Study 24887107 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater levels of illness work through networks
Number of subjects: 300
Study 22630091 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (single dose perioperative intravenous steroid)
Number of subjects: 60
Study 22630091 — intervention group
Group type: COMPARATOR
Intervention: No steroid (Control group)
Number of subjects: 60
Study 20416042 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNOB program (hospital-based intensive treatment for 1 month including diet therapy, physical training, and psychological counseling)
Number of subjects: 0
Study 20416042 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNOB program
Number of subjects: 0
Study 20416042 — intervention group
Group type: COMPARATOR
Intervention: Usual care (hospital-based treatment only)
Number of subjects: 0
Study 19102400 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (group S)
Number of subjects: 50
Study 19102400 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (group O)
Number of subjects: 50
Study 16533939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/d
Number of subjects: 507
Study 12544638 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (20 g/d for 5 days, then 3 g/d for 28 days)
Number of subjects: 17
Study 12544638 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar amounts of glucose)
Number of subjects: 17
Study 10840011 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol
Number of subjects: 98
Study 10840011 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 98
Study 8774262 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-warming (heated-air hand box at 55 degrees C) during hyperinsulinaemic euglycaemic clamp studies.
Number of subjects: 13
Study 8774262 — intervention group
Group type: COMPARATOR
Intervention: Control (box-off condition) during hyperinsulinaemic euglycaemic clamp studies.
Number of subjects: 13
Study 8774262 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-warming (2 hours) during study 2.
Number of subjects: 13
Study 8774262 — intervention group
Group type: COMPARATOR
Intervention: Control (no hand-warming) during study 2.
Number of subjects: 13
Study 8774262 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-warming (heated-air hand box at 55 degrees C) during hyperinsulinaemia.
Number of subjects: 13
Study 8774262 — intervention group
Group type: COMPARATOR
Intervention: Control (box-off condition) during hyperinsulinaemia.
Number of subjects: 13
Study 1614253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride 0.05%
Number of subjects: 57
Study 1614253 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine hydrochloride 0.25%
Number of subjects: 57
Study 1614253 — intervention group
Group type: COMPARATOR
Intervention: Cocaine 4%
Number of subjects: 57
Study 6394514 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (200 mg daily for the first two days, then adjusted based on symptom relief)
Number of subjects: 0
Study 6394514 — intervention group
Group type: COMPARATOR
Intervention: Tiapride (400 mg daily for the first two days, then adjusted based on symptom relief)
Number of subjects: 0
Study 30833130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP) for 8 weeks
Number of subjects: 30
Study 30833130 — intervention group
Group type: COMPARATOR
Intervention: Standard care control (CON)
Number of subjects: 30
Study 30470259 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose (10 mg/kg) of liposomal amphotericin B (L-AmB) given with 14 days of fluconazole (1200 mg/day) and flucytosine (100 mg/kg/day)
Number of subjects: 850
Study 30470259 — intervention group
Group type: COMPARATOR
Intervention: Seven days of amphotericin B deoxycholate (1 mg/kg/day) given alongside seven days of flucytosine (100 mg/kg/day) followed by seven days of fluconazole (1200 mg/day)
Number of subjects: 850
Study 30470259 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose (10 mg/kg) of L-AmB
Number of subjects: 850
Study 30470259 — intervention group
Group type: COMPARATOR
Intervention: Seven days of amphotericin B deoxycholate
Number of subjects: 850
Study 27630917 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal route
Number of subjects: 140
Study 27630917 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal route
Number of subjects: 140
Study 27630917 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlaminar route
Number of subjects: 140
Study 25300392 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive health checks with cardiorespiratory fitness testing
Number of subjects: 1500
Study 25300392 — intervention group
Group type: COMPARATOR
Intervention: Preventive health checks without fitness testing
Number of subjects: 1500
Study 22773591 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Number of subjects: 30
Study 22773591 — intervention group
Group type: COMPARATOR
Intervention: Potassium chloride
Number of subjects: 30
Study 20527050 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists providing high average levels of perceived Rogerian conditions
Number of subjects: 157
Study 20527050 — intervention group
Group type: COMPARATOR
Intervention: Placebo with clinical management
Number of subjects: 157
Study 20527050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 157
Study 20527050 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 157
Study 17919105 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2 (IL-2)
Number of subjects: 43
Study 17919105 — intervention group
Group type: COMPARATOR
Intervention: Boosts of ALVAC-HIV (vCP1433) and LIPO-6T followed by interleukin-2 (Vac-IL2 group)
Number of subjects: 43
Study 17919105 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immune intervention)
Number of subjects: 43
Study 17919105 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 43
Study 17919105 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV immunizations and interleukin-2
Number of subjects: 43
Study 16209895 — intervention group
Group type: EXPERIMENTAL
Intervention: I-125 seeds implantation
Number of subjects: 37
Study 11895512 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol
Number of subjects: 36
Study 11895512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10025892 — intervention group
Group type: EXPERIMENTAL
Intervention: TcRdelta and TcRgamma gene rearrangements analysis
Number of subjects: 5
Study 10025892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two target genes (TcRgamma and TcRdelta) for monitoring minimal residual disease (MRD)
Number of subjects: 5
Study 7572648 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (Eminase)
Number of subjects: 695
Study 7572648 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 695
Study 7572648 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (tissue plasminogen activator)
Number of subjects: 695
Study 2401249 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC‐9653 (375 mg/5 ml; 232.87 mg free acid)
Number of subjects: 12
Study 2401249 — intervention group
Group type: COMPARATOR
Intervention: PHT sodium (250 mg/5 ml; 229.95 mg free acid)
Number of subjects: 12
Study 7285479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 9
Study 7285479 — intervention group
Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 9
Study 7285479 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-meal state
Number of subjects: 9
Study 30705238 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital deliveries of male births
Number of subjects: 75428
Study 30705238 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-order births conditional on the first being a girl
Number of subjects: 75428
Study 30705238 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal knowledge of the sex of the fetus
Number of subjects: 75428
Study 30705238 — intervention group
Group type: COMPARATOR
Intervention: Nationally representative survey (2011 NDHS)
Number of subjects: 75428
Study 28385131 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (CD4 350‐550 cells/mm3 at ART initiation)
Number of subjects: 1566
Study 28385131 — intervention group
Group type: COMPARATOR
Intervention: Delayed ART (CD4 < 250 cells/mm3 at ART initiation or any CD4 at ART initiation)
Number of subjects: 1566
Study 28385131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and delayed ART
Number of subjects: 1566
Study 27362506 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d DHA
Number of subjects: 0
Study 27362506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25172378 — intervention group
Group type: EXPERIMENTAL
Intervention: FB-30 (high saturated fatty acid meal; S/M/P ratio 5:4:1)
Number of subjects: 11
Study 25172378 — intervention group
Group type: COMPARATOR
Intervention: F-20 (control meal; S/M/P ratio 3:4:3)
Number of subjects: 11
Study 25172378 — intervention group
Group type: EXPERIMENTAL
Intervention: F-30 (reduced saturated fatty acid meal; S/M/P ratio 3:4:3)
Number of subjects: 11
Study 22319064 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab administered in the ambulance (ambulance group, n=127)
Number of subjects: 256
Study 22319064 — intervention group
Group type: COMPARATOR
Intervention: Abciximab administered in the catheterization laboratory (hospital group, n=129)
Number of subjects: 256
Study 22319064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 256
Study 21059575 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 digital acupressure
Number of subjects: 53
Study 17908370 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying drugs (DMDs)
Number of subjects: 0
Study 17908370 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled trials
Number of subjects: 0
Study 15763392 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg per day for 4 weeks, then 10 mg per day for another 4 weeks)
Number of subjects: 24
Study 12410073 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic secretin (2 CU/kg)
Number of subjects: 85
Study 12410073 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic secretin (0.4 microg/kg)
Number of subjects: 85
Study 12410073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 10633526 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (supervised training three times a week for eight weeks)
Number of subjects: 8